Rep. Jonathan L. Jackson Sells Off Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Representative Jonathan L. Jackson (D-Illinois) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on December 12th, the Representative disclosed that they had sold between $15,001 and $50,000 in Regeneron Pharmaceuticals stock on November 13th. The trade occurred in the Representative’s “MORGAN STANLEY TRUST ACCOUNT” account.

Representative Jonathan L. Jackson also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 11/27/2024.
• Sold $15,001 – $50,000 in shares of Applied Materials (NASDAQ:AMAT) on 11/27/2024.
• Purchased $15,001 – $50,000 in shares of Church & Dwight (NYSE:CHD) on 11/13/2024.
• Sold $1,001 – $15,000 in shares of Regeneron Pharmaceuticals (NASDAQ:REGN) on 11/1/2024.
• Purchased $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 10/28/2024.
• Sold $15,001 – $50,000 in shares of ASML (NASDAQ:ASML) on 10/28/2024.
• Purchased $15,001 – $50,000 in shares of General Dynamics (NYSE:GD) on 9/24/2024.
• Sold $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 9/24/2024.
• Purchased $15,001 – $50,000 in shares of Aramark (NYSE:ARMK) on 9/19/2024.
• Sold $15,001 – $50,000 in shares of AES (NYSE:AES) on 9/19/2024.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $9.67 during midday trading on Friday, reaching $731.30. The company had a trading volume of 696,989 shares, compared to its average volume of 556,147. The firm has a 50-day moving average price of $849.77 and a 200-day moving average price of $1,004.02. The company has a market capitalization of $80.36 billion, a P/E ratio of 18.10, a P/E/G ratio of 2.32 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $728.68 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on REGN shares. Bank of America restated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Royal Bank of Canada reduced their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. Finally, Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,099.90.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $26,000. Sachetta LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Finally, Family Firm Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Representative Jackson

Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois’ 1st Congressional District. Jackson assumed office on January 3, 2023. Jackson’s current term ends on January 3, 2025. Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois’ 1st Congressional District. Jackson declared candidacy for the 2024 election. Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson’s career experience includes working as an investment analyst and an entrepreneur.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.